UBS AM’s Fulcrum Therapeutics FULC Stock Holding History

UBS AM’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.83K	Hold	773	–	–	﹤0.01%	3490
2026 Q1	$5.93K	Buy	773 +64	+9%	+$594	﹤0.01%	3427
2025 Q4	$8.02K	Buy	+709	New	+$7.21K	﹤0.01%	2895
2025 Q2	–	Sell	-703	Closed	-$2.02K	–	2655
2025 Q1	$2.02K	Buy	+703	New	+$2.58K	﹤0.01%	2633
2023 Q3	–	Sell	-25,699	Closed	-$73.2K	–	2625
2023 Q2	$73.2K	Hold	25,699	–	–	﹤0.01%	2655
2023 Q1	$73.2K	Buy	25,699 +10,899	+74%	+$97.7K	﹤0.01%	2655
2022 Q4	$108K	Hold	14,800	–	–	﹤0.01%	2490
2022 Q3	$120K	Hold	14,800	–	–	﹤0.01%	2667
2022 Q2	$72.5K	Hold	14,800	–	–	﹤0.01%	2662
2022 Q1	$350K	Buy	+14,800	New	+$209K	﹤0.01%	2558

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM's FULC Position: Q2 2026 in Review

UBS AM held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 773 shares worth $2.83K. The position accounts for ﹤0.01% of the portfolio, ranked #3490.

UBS AM first reported a position in FULC in Q1 2022 and has held it in 10 quarters since. The position peaked at $350K in Q1 2022. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

UBS AM held 773 shares of Fulcrum Therapeutics worth $2.83K as of Q2 2026.
UBS AM left its Fulcrum Therapeutics share count unchanged in Q2 2026.
Fulcrum Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3490 holding.
UBS AM first reported a position in Fulcrum Therapeutics in Q1 2022 and has held it in 10 quarters since.
UBS AM's Fulcrum Therapeutics position peaked at $350K in Q1 2022.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.